Glaxo buys UCB’s emerging market activities

BRUSSELS (Reuters) – The world’s second-largest pharmaceutical group GlaxoSmithKline Plc has agreed to buy Belgian peer UCB’s operations in a number of emerging markets for 515 million euros ($667.2 million).

Leave a Reply